US$22.9M quarterly cash outflow funds Anteris trial and manufacturing push

Anteris Technologies Global Corp. (ASX:AVR; NASDAQ:AVR) is spending heavily to turn its DurAVR transcatheter heart valve from clinical project into a potential commercial product, with the price visible in a US$26.8 million third-quarter net loss. Operating cash outflows reached US$22.9 million, while research and development spending climbed 27% year on year to US$21.3 million.

The figures are not a surprise for a development-stage medical-device company, but they sharpen the execution test. Anteris says the higher R&D bill reflected patient enrolment and field clinical-team expansion for the PARADIGM pivotal trial, alongside process development, validation work and additional manufacturing and quality staff.

PARADIGM Trial Broadens Its Geographic Footprint

During the quarter, PARADIGM continued across active sites in the United States, Canada, Denmark, the Netherlands and France. The study is designed to compare DurAVR with approved transcatheter aortic valves in an approximately 1,000-patient randomised cohort, using a one-year composite endpoint covering all-cause mortality, all stroke and cardiovascular hospitalisation.

The trial's US expansion was enabled by Medicare reimbursement eligibility secured earlier in 2026, which supported the US PARADIGM enrolment launch. After quarter-end, German regulator BfArM cleared the study's expansion into Germany, while Australian ethics approval and Therapeutic Goods Administration authorisation under the Clinical Trial Notification pathway extended the trial into Australia.

Minnesota Facility Adds Manufacturing Capacity

Anteris assumed occupancy of its Northcross facility in Brooklyn Park, Minnesota, on September 1. The site is intended to provide additional capacity for DurAVR valves, the ComASUR delivery system and related components as the company prepares for possible commercial production.

That investment contributed to the quarter's spending increase, alongside clinical activity. The new operating lease created a right-of-use asset and lease liability of about US$13.4 million, while total lease liabilities rose to US$15.9 million at September 30 from US$2.2 million at the end of 2025.

Capital Cushion Offsets Rising Cash Burn

Anteris held US$232.8 million in current cash, cash equivalents and restricted cash at September 30, plus US$3.6 million of non-current restricted cash. The balance largely reflects the approximately US$320 million raised through January's public offering and Medtronic private placement, following which the company also established a US$250 million at-the-market facility. No shares had been sold under that ATM programme by quarter-end.

Revenue remains small by comparison, rising 21% to US$519,000 for the quarter and 26% to US$2.0 million for the nine-month period. The business continues to generate most of that revenue from regenerative tissue products, while management says it does not expect significant product revenue until regulatory approval and commercial sales of its lead device begin. Anteris says its existing cash should fund operating requirements for at least the next 12 months under its current plan, although it also expects to need additional capital for its longer-term goals.

Financial Reporting Weaknesses Remain Unresolved

The filing carries a less visible but important qualification: previously reported material weaknesses in internal control over financial reporting remained unremediated at September 30. Anteris said it had improved control processes, documentation, segregation of duties and review procedures, but remediation still requires validation and testing before effectiveness can be established.

The next meaningful evidence will come from the trial's pace and quality of enrolment, rather than from the company's modest product revenue. At the same time, investors will need to weigh the cash balance against a quarterly operating burn that is rising as Anteris builds both the clinical programme and the infrastructure intended to support it.